Viad Corp. (VVI) Tops Q3 EPS by 2c, Beats on Revenues
Get Alerts VVI Hot Sheet
Price: $42.51 --0%
Financial Fact:
Dividends declared per common share: 0.1
Today's EPS Names:
SVBT, ZEO, OTLK, More
Financial Fact:
Dividends declared per common share: 0.1
Today's EPS Names:
SVBT, ZEO, OTLK, More
Join SI Premium – FREE
Viad Corp. (NYSE: VVI) reported Q3 EPS of $1.33, $0.02 better than the analyst estimate of $1.31. Revenue for the quarter came in at $339.1 million versus the consensus estimate of $327.59 million.
2017 Full Year Guidance
- Consolidated revenue is expected to increase by approximately 7% to 8% from 2016 full year revenue, driven primarily by incremental contributions from acquisitions completed during 2016 and continued growth in the underlying business, partially offset by unfavorable currency translation of approximately $5 million, negative show rotation of about $10 million and a $13 million reduction in revenue from package tours as the company completes the rationalization of that line of business in Canada.
- Consolidated adjusted segment EBITDA is expected to be in the range of $153 million to $155 million, as compared to prior guidance of $153.5 million to $157.5 million and $130.2 million* in 2016. The reduction versus prior guidance primarily reflects a lower EBITDA contribution from ON Services than previously anticipated as the company continues to focus on integration efforts that will drive future revenue and cost synergies. Largely offsetting that reduction is an improved outlook for Pursuit.
- Exchange rates are assumed to approximate $0.81 U.S. Dollars per Canadian Dollar and $1.31 U.S. Dollars per British Pound during the 2017 fourth quarter. Exchange rate variances are expected to impact 2017 full year results as follows:
For earnings history and earnings-related data on Viad Corp. (VVI) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
- CaliberCos Inc (CWD) Misses Q2 EPS by 43c; Offers Guidance
- Silexion Therapeutics (SLXN) Tops Q2 EPS by 793c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share